Defence Therapeutics Inc Class A
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Amie Phinney
- Full Time Employees
- 5
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- 7171 Rue Frederick-Banting Vancouver QC Canada H4S1Z9
- IPO Date
- May 7, 2021
- Website
- defencetherapeutics.com
- Similar Companies
- Business
- Defence Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of innovative immunotherapy products for the treatment of various cancers and infectious diseases. Its core products include intratumoral immunotherapies, targeted protein conjugates, and mRNA vaccine platforms designed to stimulate the immune system; key product candidates include vaccines and antibody-based therapies. The company operates primarily in Canada, with activities extending to the United States and international markets. Founded in 2010, Defence Therapeutics is headquartered in Montreal, Quebec, Canada. Recently, Defence Therapeutics has made strategic progress by advancing its pipeline of intratumoral and mRNA-based immunotherapies, expanding its clinical development programs to address multiple cancer types and infectious diseases. The company has engaged in partnerships and collaborations aimed at accelerating development and commercialization efforts, and it continues to explore new therapeutic platforms and delivery technologies. There have been no recent name changes or reorganizations reported, but ongoing operational developments focus on advancing proprietary technology platforms and expanding its portfolio of therapeutic candidates. The company serves the biotechnology and pharmaceutical industry segments, targeting healthcare providers, research institutions, and patients requiring novel immunotherapeutic treatments. Defence Therapeutics leverages its proprietary technology to create next-generation immune-activating therapies across oncology and infectious disease markets, positioning itself as an emerging player in the global immunotherapy sector. It is a publicly traded company listed on the Canadian Securities Exchange under the ticker DTC.CN.
Company News
Defence Therapeutics Wins Best Poster Award and Takes Center Stage at World ADC San Diego 2026, a Key Recognition in the Field Highlighting the Potential of Its Accum Platform
Defence Therapeutics Inc. (OTCMKTS:DTCFF) Stock Short Interest Report for September
Defence Therapeutics to Take the Stage at World ADC San Diego to Discuss the Next Frontier in Antibody-Drug Conjugates
Defence Therapeutics Appoints Finance Executive Sherry Aulin to Its Board of Directors
Defence Therapeutics Provides Corporate Update as Company Executes on Strategic Priorities
Defence Therapeutics CEO Highlights Recent Progress and Outlines Strategic Priorities in Letter to Shareholders
Defence Therapeutics Provides Updates on Sharing Agreement
Defence Therapeutics Expands Radiopharmaceutical Development Strategy with Alpha and Beta-Emitter Programs
Defence Therapeutics Strengthens Radiopharmaceutical Leadership with Appointment of Dr. Ryan Simms as Chief Operating Officer and Head of Radiopharmaceutical Programs
Defence Therapeutics Appoints Dr. Amie Phinney as President and Chief Executive Officer
Defence Therapeutics Opens New Office in Hamilton to Expand Its Accum Radiopharmaceutical Platform
Defence Therapeutics to Participate in Bio International Convention 2026 Next Week for Strategic Partnership Discussions
Defence Therapeutics Appoints Seasoned Biopharmaceutical Executive Dr John Beaver to Its Board of Directors
Defence Therapeutics Appoints Antibody Drug Conjugates Pioneer Dr. John Lambert to Its Board of Directors
Defence Therapeutics Strengthens Its Scientific Advisory Board with the Appointment of Dr. Sarkis Meterissian
Defence Therapeutics Enhances In-House ADC Development Platform with Expanded Analytical and Cellular Testing Capabilities
Defence Therapeutics Announces Grant of Restricted Stock Units
Defence Therapeutics Announces Warrant Terms Amendment
Defence Therapeutics Announces Closing of Private Placement of Units for Gross Proceeds of $9,595,000
Defence Therapeutics to Showcase Accum Platform at Key International Industry Events in March